These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6467149)

  • 1. Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies.
    Voelcker G; Wagner T; Wientzek C; Hohorst HJ
    Cancer; 1984 Sep; 54(6 Suppl):1179-86. PubMed ID: 6467149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of the protector thiol L-cystein on the toxic and therapeutic responses of stabilized "activated" cyclophosphamide (4-(S-ethanol)-sulfido-cyclophosphamide).
    Voelcker G; Laber P; Rockinger H; Wientzek C; Hohorst HJ
    Invest New Drugs; 1984; 2(2):253-9. PubMed ID: 6469518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intracavitary chemotherapy of S 180 ascites sarcoma in mice with 4-(S-ethanol)-sulfido-cyclophosphamide in combination with protector thiols].
    Voelcker G; Jaschke A; Wrabetz E; Hohorst HJ
    Arzneimittelforschung; 1984; 34(10):1291-8. PubMed ID: 6440565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The enzymatic basis of cyclophosphamide specificity.
    Hohorst HJ; Bielicki L; Voelcker G
    Adv Enzyme Regul; 1986; 25():99-122. PubMed ID: 3028054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
    Voelcker G; Haeglsperger R
    Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].
    Wagner T; Heydrich D; Voelcker G; Hohorst HJ
    J Cancer Res Clin Oncol; 1980 Jan; 96(1):79-92. PubMed ID: 7358774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
    Voelcker G; Bielicki L; Hohorst HJ
    J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracavitary chemotherapy with activated cyclophosphamides and simultaneous systemic detoxification with protector thiols in Sarcoma 180 ascites tumor.
    Wagner T; Mittendorff F; Walter E
    Cancer Res; 1986 May; 46(5):2214-9. PubMed ID: 3697966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.
    Wagner T; Zink M; Schwieder G
    J Cancer Res Clin Oncol; 1987; 113(2):160-5. PubMed ID: 3104347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide.
    Gurtoo HL; Hipkens JH; Sharma SD
    Cancer Res; 1981 Sep; 41(9 Pt 1):3584-91. PubMed ID: 7260917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.
    Mohrmann M; Ansorge S; Schmich U; Schönfeld B; Brandis M
    Pediatr Nephrol; 1994 Apr; 8(2):157-63. PubMed ID: 7517170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
    Chan KK; Hong PS; Tutsch K; Trump DL
    Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the human pharmacokinetics of isophosphamide (NSC-109724).
    Allen LM; Creaven PJ; Nelson RL
    Cancer Treat Rep; 1976 Apr; 60(4):451-8. PubMed ID: 1277221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations.
    Wagner T; Fenneberg K
    Arzneimittelforschung; 1984; 34(3):313-6. PubMed ID: 6539613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effective levels of cyclophosphamide and metabolites in pleural effusions during intravenous therapy (author's transl)].
    Wagner T; Heydrich D
    Arzneimittelforschung; 1982; 32(5):566-8. PubMed ID: 7201835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of cyclophosphamide from oral formulations.
    Wagner T; Fenneberg K
    Eur J Clin Pharmacol; 1984; 26(2):269-70. PubMed ID: 6723768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.
    Bielicki L; Voelcker G; Hohorst HJ
    J Cancer Res Clin Oncol; 1983; 105(1):27-9. PubMed ID: 6300134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
    Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
    J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.
    Peter G; Hohorst HJ
    Cancer Chemother Pharmacol; 1979; 3(3):181-8. PubMed ID: 527208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.